npj Breast Cancer (Aug 2024)

Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502

  • Daniel G. Stover,
  • Roberto Salgado,
  • Oleksander Savenkov,
  • Karla Ballman,
  • Erica L. Mayer,
  • Mark Jesus M. Magbanua,
  • Sherene Loi,
  • Mark Vater,
  • Kristyn Glover,
  • Mark Watson,
  • Yujia Wen,
  • W. Fraser Symmans,
  • Charles Perou,
  • Lisa A. Carey,
  • Ann H. Partridge,
  • Hope S. Rugo

DOI
https://doi.org/10.1038/s41523-024-00683-x
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 5

Abstract

Read online

Abstract Association of stromal tumor-infiltrating lymphocytes (sTILs) with survival outcomes among patients with metastatic breast cancer (MBC) remains unclear. The primary objective was to evaluate the association of sTILs with progression-free survival in randomized phase III trial CALGB 40502. sTILs were associated with progression-free and overall survival in chemotherapy-treated MBC when controlling for treatment arm; however, this effect did not remain significant after additional adjustment for hormone receptor status. CALGB is now part of the Alliance for Clinical Trials in Oncology. Trial Registration: ClinicalTrials.gov: NCT00785291.